NDA 018891 · Lavipharm
Catapres-Tts-3
Clonidine · Transdermal · Central alpha-2 Adrenergic Agonist
Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Oct 10, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
276
54 Phase 3, 19 recruiting
FAERS reports
2,134
564 serious, 61 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
INDICATIONS AND USAGE Clonidine transdermal system is indicated in the treatment of hypertension. It may be employed alone or concomitantly with other antihypertensive agents.
Mechanism: System Structure and Components Clonidine Transdermal System, USP is a multi-layered film, 0.2 mm thick, containing clonidine as the active agent. The system areas are 3.5 cm 2 (Clonidine Transdermal System USP, 0.1 mg/day), 7.0 cm 2 (Clonidine Transdermal System USP, 0.2 mg/day) and 10.5 cm 2 (Clonidine Transdermal System USP, 0.3 mg/day) and the amount of drug released is directly proportional to the area (see Release Rate Concept ). The composition per unit area is the same for all three doses. Proceeding from the visible surface towards the surface attached to the skin, there are four...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 1984 Original approval · Type 3 - New Dosage Form
3 products under this application
- CATAPRES-TTS-3 · CLONIDINE 0.3MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB
- CATAPRES-TTS-1 · CLONIDINE 0.1MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB
- CATAPRES-TTS-2 · CLONIDINE 0.2MG/24HR · SYSTEM, TRANSDERMAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Clonidine" as an intervention, any sponsor and status, largest first.
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- PeriOperative ISchemic Evaluation-2 TrialPivotal-lookingCompleted
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT01082874 · 10,010 participants · Start Jul 2010 · Primary completion Mar 2014
Drug: Active Clonidine; Placebo Clonidine and 2 more · For: Cardiovascular Disease
Sites: Cleveland, Ohio; Rosario, Argentina; Parkville, Australia · 23 sites in all
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- Resistant Hypertension Optimal TreatmentPivotal-lookingStatus unknown
Instituto do CoracaoGovernment (non-federal)
NCT01643434 · 2,000 participants (planned) · Start Aug 2012 · Primary completion Dec 2013
Drug: Spironolactone; Clonidine · For: Hypertension
Sites: São Paulo, Brazil
- Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)Pivotal-lookingCompleted
University of EdinburghAcademic, hospital or other
NCT03653832 · 1,404 participants · Start Dec 11, 2018 · Primary completion Dec 14, 2023
Drug: Dexmedetomidine; Clonidine and 1 more · For: Critical Illness
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Blackpool, United Kingdom · 38 sites in all
- Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS StudyPivotal-lookingCompleted
Heart Care FoundationAcademic, hospital or other
NCT00421863 · 1,111 participants · Start Feb 2005 · Primary completion Jan 2009
Drug: Triatec 10 mg; Triatec HCT 5 and 7 more · For: Hypertension
Sites: San Pietro Vernotico, Italy; Chiari, Italy; Trebisacce, Italy · 45 sites in all
- Dexmedetomidine or Clonidine Infusion for Prevention of Delirium After Open Heart SurgeryPivotal-lookingActive, not recruiting
Oslo University HospitalAcademic, hospital or other
NCT05029050 · 900 participants (planned) · Start Jan 17, 2022 · Primary completion Jul 31, 2026
Drug: Dexmedetomidine; Clonidine and 1 more · For: Delirium; Cognitive Decline; Frailty
Sites: Bergen, Norway; Oslo, Norway; Tromsø, Norway · 5 sites in all
- Nephropathy In Type 2 Diabetes and Cardio-renal EventsPivotal-lookingCompleted
University of Campania Luigi VanvitelliAcademic, hospital or other
NCT00535925 · 850 participants · Start Oct 2005 · Primary completion Dec 2011
Drug: SoC therapy; irbesartan and 12 more · For: Diabetic Nephropathy
Sites: Naples, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- application site pruritus347
- application site erythema304
- drug ineffective280
- blood pressure increased254
- application site rash198
- product adhesion issue187
- hypertension145
- application site irritation123
- wrong technique in product usage process100
- headache96
- application site vesicles83
- blood pressure inadequately controlled83
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 57 |
| 2006 | 52 |
| 2007 | 157 |
| 2008 | 290 |
| 2009 | 249 |
| 2010 | 170 |
| 2011 | 95 |
| 2012 | 70 |
| 2013 | 17 |
| 2014 | 44 |
| 2015 | 54 |
| 2016 | 68 |
| 2017 | 103 |
| 2018 | 81 |
| 2019 | 110 |
| 2020 | 73 |
| 2021 | 83 |
| 2022 | 52 |
| 2023 | 62 |
| 2024 | 35 |
| 2025 | 66 |
| 2026 | 100 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.
Bohn E, Goren K, Switzer L, et al. · Dev Med Child Neurol 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Alpha2 adrenergic agonists for the management of opioid withdrawal.
Gowing L, Farrell M, Ali R, et al. · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Clonidine for sedation in the critically ill: a systematic review and meta-analysis.
Wang JG, Belley-Coté E, Burry L, et al. · Crit Care 2017 · Meta-Analysis, Systematic Review
- What is the place of clonidine in anesthesia? Systematic review and meta-analyses of randomized controlled trials.
Sanchez Munoz MC, De Kock M, Forget P · J Clin Anesth 2017 · Meta-Analysis, Systematic Review
- Clonidine versus chlordiazepoxide in acute alcohol withdrawal: a preliminary report.
Baumgartner GR · South Med J 1988 · Clinical Trial, Comparative Study
- Lack of effect of clonidine on stuttering in children.
Althaus M, Vink HJ, Minderaa RB, et al. · Am J Psychiatry 1995 · Clinical Trial, Randomized Controlled Trial
Sponsor: Lavipharm · Also marketed as Catapres-Tts-1, Catapres-Tts-2
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.